Welcome to our dedicated page for Arvinas news (Ticker: ARVN), a resource for investors and traders seeking the latest updates and insights on Arvinas stock.
Arvinas, Inc. develops targeted protein degradation medicines through its PROTAC protein degrader platform. Company updates center on VEPPANU (vepdegestrant), developed with Pfizer and approved by the FDA for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after endocrine-based therapy, as well as regulatory, clinical, and corporate milestones tied to that program.
Arvinas news also covers investigational PROTAC degraders across oncology, neurology, and neuromuscular disease, including ARV-102 for LRRK2-driven neurodegenerative disorders, ARV-806 for KRAS G12D-mutated cancers, ARV-393 for BCL6-driven lymphoma, and ARV-027 as a polyQ-AR degrader. Recurring items include clinical data presentations, financial results, corporate updates, investor conferences, and governance changes.
Arvinas (Nasdaq: ARVN) held its fourth company-wide Impact Day on May 17, 2026, uniting employees across Connecticut, Greater Boston, and the U.S. in community service. Projects supported organizations including Ronald McDonald House, Fleece & Thank You, American Cancer Society Hope Lodge, Save the Sound, Boys & Girls Club, and Community Soup Kitchen.
Arvinas (Nasdaq: ARVN) reported Q1 2026 results and major milestones, including FDA approval of VEPPANU (vepdegestrant), the first approved PROTAC, for ESR1‑mutated ER+/HER2‑ advanced breast cancer and a global licensing deal with Rigel.
Q1 revenue was $15.6M versus $188.8M a year ago, mainly from Pfizer collaborations. GAAP R&D fell to $60.3M from $90.8M, and GAAP G&A to $19.1M from $26.6M. Cash and securities were $614.9M, expected to fund operations into 2H 2028. The company highlighted positive ARV‑102 Phase 1 biomarker data, multiple pipeline advances, and appointed Randy Teel as President and CEO.
Arvinas (Nasdaq: ARVN) and Pfizer signed a global license agreement granting Rigel exclusive rights to develop, manufacture, and commercialize VEPPANU (vepdegestrant), the first FDA‑approved PROTAC.
Arvinas and Pfizer receive $70M upfront, $15M transition payments, up to $320M milestones, and mid‑teens to mid‑20s tiered royalties.
Arvinas (Nasdaq: ARVN) will report first quarter 2026 financial results on May 12, 2026 with a live webcast at 8:00 a.m. ET. Management will review Q1 results and provide a corporate update.
Investors can access the webcast under Events and Presentations on the Arvinas investor website; a replay will be posted after the event.
Arvinas (Nasdaq: ARVN) announced FDA approval of VEPPANU (vepdegestrant) on May 1, 2026, for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after progression on endocrine therapy. VEPPANU is the first FDA‑approved PROTAC. VERITAC-2 (n=270 ESR1m) showed a 43% risk reduction in PFS (HR 0.57); median PFS 5.0 vs 2.1 months. Approval occurred before the June 5, 2026 PDUFA date. Arvinas and Pfizer will select a third-party commercial partner. Important safety issues include QT prolongation and common lab abnormalities.
Arvinas (Nasdaq: ARVN) reported Phase 1 results for ARV-102 showing approximately ≥50% LRRK2 degradation in CSF by day 14, maintained through day 28, across 20–80 mg daily doses. ARV-102 showed dose-dependent CSF exposure, reduced endolysosomal and neuroinflammatory biomarkers (e.g., CD68, GPNMB), and was generally well tolerated with no SAEs, supporting further development including a planned Phase 1b in PSP in Q2 2026.
Arvinas (Nasdaq: ARVN) will present Phase 1 human data for ARV-102, an oral PROTAC degrader targeting LRRK2, at AD/PD 2026 in Copenhagen. The presentation on March 18, 2026 at 3:30 PM CET covers safety, pharmacokinetics, and pharmacodynamics in participants with Parkinson’s disease.
Arvinas (Nasdaq: ARVN) reported 4Q and full‑year 2025 results and a corporate update on Feb 24, 2026. Key items: cash, cash equivalents and marketable securities of $685.4M at year‑end; cash runway into the second half of 2028; multiple clinical readouts and program milestones planned in 2026; Randy Teel named President and CEO.
Pipeline progress includes ARV‑102 AD/PD data in March 2026, ARV‑806 and ARV‑393 clinical updates in 2026, initiation of ARV‑027 healthy‑volunteer trial, and ARV‑6723 Phase 1 planned mid‑2026.
Arvinas (Nasdaq: ARVN) said management will participate in four investor conferences in early March 2026, including TD Cowen, Leerink Global Healthcare, Barclays Global Healthcare, and Jefferies Biotech on the Beach.
Each appearance is a fireside chat with specific times on March 3, 9, 10 and 11; replays will be posted in the Events and Presentations section of the company website.
Arvinas (Nasdaq: ARVN) will report fourth quarter and full year 2025 financial results on February 24, 2026. Management will review results and provide a corporate update via a live webcast at 8:00 a.m. ET.
The webcast is available under “Events and Presentations” on Arvinas’ investor website, and a replay will be posted on www.arvinas.com after the event.